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Abstract
Background: ARF6 (ADP-ribosylation factor 6) small GTP binding protein plays critical roles in actin cytoskeleton
rearrangements and membrane trafficking, including internalisation of G protein coupled receptors (GPCR). ARF6 operates
by cycling between GDP-bound (inactive) and GTP-bound (active) forms and is a potential regulator of GPCR-mediated
uterine activity during pregnancy and labour. ARF6 contains very low intrinsic GTP binding activity and depends on GEFs
(guanine nucleotide exchange factors) such as CYTH3 (cytohesin 3) to bind GTP. ARF6 and CYTH3 were originally cloned
from human placenta, but there is no information on their expression in other reproductive tissues.
Methods: The expression of ARF6, ARF1, and CYTH1-4 was investigated by measuring mRNA (using RT-PCR) and protein
levels (using immunoblotting) in samples of myometrium obtained from non-pregnant women, and women with normal
pregnancies, before or after the spontaneous onset of labour. We also analysed myometrial samples from women with
spontaneous preterm labour and from women with complicated pregnancies requiring emergency preterm delivery. The
GST)-effector pull down assay was used to study the presence of active ARF6 and ARF1 in all myometrial extracts.
Results: ARF6, ARF1 and CYTH3 but not CYTH1, CYTH2 and CYTH4 were expressed in all samples and the levels did not
change with pregnancy or labour. However, ARF6 and CYTH3 but not ARF1 levels were significantly reduced in complicated
pregnancies. The alterations in the expression of ARF6 and its GEF in human myometrium indicate a potential involvement
of this signalling system in modulating the response of myometrial smooth muscle in complicated pregnancies. The levels
of ARF6-GTP or ARF1-GTP did not change with pregnancy or labour but ARF6-GTP levels were significantly decreased in
women with severe complications of pregnancy.
Conclusions: We have demonstrated a functional ARF6 system in human myometrium and a correlation between ARF6
level and activity in uterine and abnormal pregnancy.
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Introduction
Preterm birth, defined as delivery before 37 weeks of gestation,
is one of the major causes of perinatal mortality and disability in
surviving infants [1,2]. Despite considerable research, the aetiol-
ogy and the mechanism of preterm birth are not well understood
and as a result, no satisfactory effective preventative therapy has
been developed. There is a need to improve our understanding of
the intracellular molecular events involved in the maintenance of
uterine quiescence during pregnancy, and in initiating successful
parturition at term, in order to establish the basis for the
development of new therapeutic strategies to prevent preterm
birth.
The myometrial smooth muscle layer of the uterus remains
relatively relaxed and unresponsive during pregnancy, while it
becomes highly contractile at the time of parturition. Smooth
muscle contractility depends on the interaction between polymer-
ised actin filaments and activated regulatory myosin light chains
(MLCs). An increase in intracellular calcium (Ca
2+)i concentration
driven by membrane depolarization through action potentials or
generated by stimulatory GPCR activates calmodulin dependent
MLC kinase, which in turn phosphorylates MLC to cause
contraction. Contractions are reversed by a decline in [Ca
2+]i
and the activity of myosin phosphatase (MP) [3] which dephos-
phorylates MLC to cause relaxation [4]. Uterine smooth muscle
contractions are also regulated by several Ca
2+ independent
pathways: inhibition of MP by ROCK [5] resulting in Ca
2+
sensitization, or through the activation of MP by cyclic nucleotide
dependent kinases [6].
In the uterus, GPCRs coupled to Gs, e.g. b2- adrenoceptor
(ADRB2), prostacyclin receptor (PTGIR), prostaglandin E1
receptor (PTGER)2 and luteinizing hormone chorionic gonado-
tropin receptor (LHCGR), promote relaxation by increasing
intracellular cyclic AMP (cAMP) and activating protein kinase A
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30(PKA) [7]. Premature desensitization or loss of signalling of any of
these receptors may cause contractions resulting pre-term birth.
On the other hand, increased expression of GPCRs coupled to Gq
or Gi, e.g. oxytocin receptor (OXTR), PTGER1, PTGER3 and
thromboxane A2 receptor (TBXA2) increase contractility through
activation of the phospholipase C (PLC)/inositol (1,4,5)trispho-
sphate (IP3)/Ca
2+ pathway by Gq, or by inhibiting cAMP
production through Gi [8,9]. Additional regulatory effects are
obtained through GPCR dependent and independent activation of
protein kinase C (PKC), the mitogen-activated protein kinase
(MAPK) pathway and phospholipase D (PLD) [10]. Moreover, in
addition to changes at the level of GPCR signalling, recent
evidence suggests that the involvement of small GTP binding
proteins and their GEFs may be crucial [3,11]. Rho small GTP
binding protein regulates actin-myosin interaction in uterine
smooth muscles by activating RHO associated kinase (ROCK)
[8,12]. Moreover ARF6 small GTP binding protein may be
involved in regulating uterine sensitivity to agonists but the
presence of the ARF6 system in human myometrium has never
been investigated [3] and this was the primary purpose of this
manuscript.
ARF6 is a member of the ARF family of small GTP binding
proteins, which regulate intracellular membrane traffic by cycling
between active GTP- and inactive GDP-bound forms. ARFs
depend on guanine nucleotide exchange factors (GEFs) for
activation and GTPase activating proteins (GAPs) for inactivation.
Among the six known mammalian ARF isoforms (ARFs1-6),
ARF1 and ARF6 are the best characterised. ARF1 localises to and
acts at the Golgi whereas ARF6 localises to and acts at the cell
periphery [13]. ARF6 plays critical roles in actin cytoskeleton
rearrangements and membrane trafficking, including internaliza-
tion of GPCR [14]. ARF6 is activated by the cytohesin family of
GEFs, which consists of four members (CYTH1-4) in humans
[13]. ARF6 and CYTH3 (also known as GRP1 [general receptor
for phosphoinositides 1] or PSCD3 [pleckstrin homology, Sec7
and coiled-coil domains 3]) are expressed at very high levels in
human placenta from which they were originally cloned [15].
ARF6 has cellular functions that may modulate uterine activity
during pregnancy and labour, for instance it inhibits LPA-induced
stress fibre formation in cell models by inhibiting RHO activation
[16]. In rat myometrium ARF6 is required for PLD activation
[17]. ARF6 interacts with the a subunit of heterotrimeric G
proteins [18] and is involved in the intracellular trafficking of
many GPCRs [19] including ADRB2 [20], LHCGR [14,21] and
receptors of the vasopressin/oxytocin family [19].
The aim of this study was to assess ARF1, ARF6 and CYTH1-4
expression and ARF1 and ARF6 activation in myometrium in
various conditions of pregnancy and labour. We were able to
demonstrate for the first time the presence of ARF1, ARF6 and
CYTH3 but not CYTH1, CYTH2 and CYTH4 mRNA and their
protein products in non-pregnant and pregnant myometrial
tissues. We have also measured the level of GTP-bound ARF1
and ARF6 in myometrium and found that the levels are normally
high, suggesting a functional involvement of these GTPases in the
uterus, however the levels of total ARF6, ARF6-GTP and CYTH3
fall significantly in association with pregnancy complications that
result in emergency preterm deliveries.
Materials and Methods
Reagents and Antibodies
An anti-ARF6 mouse monoclonal and an anti-CYTH3 goat
polyclonal antibodies were from SantaCruz Biotech. An anti-
CYTH1 mouse monoclonal and an anti-ARF1 rabbit polyclonal
antibodies were gift from Prof. Sylvain Bourgoin (Laval University,
Quebec, Canada). An anti-CYTH2 and an anti-a tubulin mouse
monoclonal antibodies were purchased from Sigma. An anti-
CYTH4 rabbit polyclonal antibody was from Abcam. HRP-
conjugated anti-mouse, anti-rabbit and anti-goat IgG, ECL
reagents and Glutathione Sepharose beads were from GE
Healthcare. All others chemicals were from Sigma unless
otherwise specified.
Cell Culture
MDA-MB-231 breast cancer cells were cultured in Dulbecco’s
modified Eagle’s medium (DMEM) containing 2 mM glutamine,
100 U/ml of penicillin, 0.1 mg/ml of streptomycin sulphate and
10% fetal calf serum under 5% CO2 at 37uC.
Myometrial Tissue Collection
Myometrial samples were obtained, as described previously [8],
from non-pregnant (NP) pre-menopausal women who were
undergoing hysterectomy for benign gynaecological disorders
including fibroids or menorrhagia, and from pregnant women at
term (range 37–40 weeks of gestation) who had elective caesarean
sections performed before the onset of labour (not in labour; NIL),
or emergency sections during spontaneous labour (SL). Indications
Table 1. The primer sequences used for RT-PCR analysis of ARF6, CYTH3 and GAPDH mRNA expression in the human
myometrium.
Gene Accession number Forward primer Reverse primer Amplimer location
Amplified
PCR product
size (bp) References
ARF1 M36340 59-GCCAGTGTCCTTCCACCTGTC-39 59GCCTCGTTCACACGCTCTCTG-39 50–385 336 [44]
ARF6 NM_001663 59-ATGGGGAAGGTGCTATCCAAA-39 59-GCAGTCCACTACGAAGATGAGACC-39 622–891 270 [45]
CYTH1 M85169 59-TAGCTAATGAAATTGAAAACCTGGGAT-39 59-TTCATGGCAATGAACCTCTCCACAGTG-
39 200–722
523 [28]
CYTH2 X99753 59-CAGTGAAGCCATGAGCGAGGT-39 59-TTCATGGCCACAAAGCGCTCCAGG-39 127–650 524 [28]
CYTH3 NM_004227 59-ATCGACAATCTAACTTCCGTA-39 59-ATGGCGATGAACCGTTCTGCCG-39 258–766 509 [28]
CYTH4 NM_013385 59-TGTTTGCCCAAATCGACTGCT-39 59-TCATCCACCTTCTGCACCGAG-39 246–1060 815 [28]
GAPDH NM_002046 59-ACCACAGTCCATGCCATCAC-39 59-TCCACCACCCTGTTGCTGTA-39 586–1037 452 [46]
The starting and end position of the mRNA sequences amplified by RT-PCR are numbered (amplimer location) according to the sequences in the NCBI data base.
doi:10.1371/journal.pone.0037954.t001
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tation, previous caesarean section or placenta praevia. Labour was
defined by regular uterine contractions and cervical dilatation
.4 cm. Samples were also collected from women who had
emergency caesarean sections preterm (range 30–35 weeks), either
in spontaneous idiopathic preterm labour, with no evidence of
infection for breech or fetal distress (PT-SL) or in the absence of
labour for complications of pregnancy including intrauterine
growth restriction, pre-eclampsia, or antepartum haemorrhage
(PT-NIL). There were four women in each group. Myometrial
strips were taken from the upper border of the uterine incision
taking care to exclude serosal or decidual tissue. Tissues were
rinsed quickly in normal saline and snap-frozen and stored in
liquid nitrogen. The study was approved by the North Somerset
and South Bristol Research Ethics Committee. Written informed
consent was obtained from all women.
Reverse Transcription-Polymerase Chain Reaction (RT-
PCR)
Total RNA was isolated from the human myometrial tissue
samples according to the manufacturer’s instructions using
AurumTM total RNA Mini Kit (Biorad) and treated with DNAase
I to eliminate any residual genomic DNA contamination. DNAse I
treated RNA was reverse transcribed to complementary DNA
(cDNA) using Superscript II Reverse Transcriptase system
(Invitrogen) and by following the supplier’s instructions. Briefly,
1 mg of RNA was mixed with 50 ng of random hexamer,
10 nmoles of dNTPs (deoxyribonucleotide trisphosphates), 50
units of superscript II Reverse Transcriptase enzyme and 40 units
of RNase OUT Recombinant RNase Inhibitor in a 20 ml reaction
volume and incubated for 50 min at 42uC and 15 min at 70uC.
The reaction mixture was then treated with 2 U of RNase H at
37uC for 20 min to degrade any un-transcribed RNA. The cDNAs
samples were stored at 220uC for further use in PCR.
The ARF1, ARF6, CYTH1-4 and GAPDH gene fragments
were amplified from human myometrial cDNA by PCR. The
sense and antisense primers used for PCR and the PCR
product sizes are shown in Table 1. PCR reaction was
performed in a final volume of 25 ml containing 1 unit Taq
DNA polymerase, 0.2 mM dNTPs, 0.2 mM primers and 1 mlo f
cDNA or 10 ng of plasmid DNA. The amplification was carried
out by an initial denaturation at 94uC for 2 min followed by
either 30 cycles (for plasmid DNA) or 25, 30, 35 and 40 cycles
(for cDNA) of denaturation at 94uC for 30 sec, annealing at
60uC (50uC for CYTH3) for 30 sec and elongation at 72uC for
1 min. The reaction was terminated by a 5-min elongation step
at 72uC. 35 cycles of the PCR reaction had the linear range of
amplification of cDNA and was used for subsequent PCR
reactions. The specificity of PCR was assessed by testing for
genomic DNA contamination using two controls: cDNA samples
prepared by RT without adding reverse transcriptase and water
in place of cDNA. RT-PCR reactions were carried out only
with the samples that were free of DNA contamination.
Western Blotting
Myometrial tissue ground into a fine powder in liquid nitrogen
was homogenised in ice-cold modified RIPA lysis buffer (50 mM
Tris-HCL, pH 7.5, 150 mM NaCl, 1% Triton x-100, 0.5% (w/v)
sodium deoxycholate, 0.1% (w/v) SDS, 10 mM MgCl2) with 1%
protease inhibitors mix (Sigma). MDA-MB-231 cells were also
lysed in the RIPA lysis buffer. Protein concentration of the lysates
was determined using the bicinchoninic acid protein assay (Sigma)
as per the manufacturer’s instructions using BSA as a protein
standard. Tissue homogenate or cell lysate proteins (50 mg) were
separated using SDS-PAGE and transferred to a polyvinylidene
fluoride (PVDF) membrane (Millipore) in ice-cold transfer buffer
(25 mM Tris, 125 mM Glycine and 20% methanol) by using
semidry blotting system (Biorad). All the incubations were carried
out at room temperature unless otherwise specified. The binding
sites on membrane were blocked using BLOTTO (5% [w/v]
skimmed milk powder in TBS-T, 0.1% Tween-20 in TBS) for one
hour before incubating with a primary antibody (an anti-ARF6
[1:200 dil.], an anti-ARF1 [1:2000 dil.], an anti-CYTH1
[1:500 dil.], an anti-CYTH2 [1:500 dil.], an anti-CYTH3
[1:1000 dil.], an anti-CYTH4 [1:500 dil.] or mouse monoclonal
anti-a-tubulin [1:10,000 dil.]) overnight at 4uC in BLOTTO. The
blots were then washed in TBS-T for 15 minutes for three times
and incubated with HRP-conjugated an anti-mouse or anti-rabbit
or anti-goat IgG antibody (1:2500 dil.) in BLOTTO for 1 hr.
Following the wash of the membrane for 15 min for three times,
the protein bands on the membrane were visualized using ECL
reagent [22].
Immunohistochemistry
Immunohistochemistry was carried out as described [8]. Briefly,
paraffin-embedded tissue sections were incubated with 0.3%
hydrogen peroxide for 10 min to block endogenous peroxidase
activity and blocked with 2.5% horse serum for 30 min to reduce
non-specific binding. The sections were incubated with primary
antibody (an anti-ARF6 mouse monoclonal antibody [1:50 dil.] or
anti-CYTH3 goat polyclonal antibody [1:200 dil.]) for 45 min at
room temperature, biotinylated an anti-mouse or an anti-goat
secondary antibody (Vectastain Quick Universal Kit) for 20 min,
streptavidin peroxidase reagent for 20 min, and diaminobenzidine
chromogen solution for 5 min, and then were counterstained in
Mayers Haematoxylin for 1 min, dehydrated in alcohol, immersed
in xylene, and mounted.
GST-GGA3 PBD Pull Down Assay
The glutathione S-transferase (GST)-Golgi associated, gamma
adaptin ear containing, ARF binding protein 3 (GGA3) protein
binding domain (PBD; amino acids 1–316) pull-down assay was
performed as described [23,24]. Since the GGA3 PBD pull-downs
the active form of all ARF isoforms, only Western blotting of the
pull downs with an anti-ARF6 or an anti-ARF1 antibody makes
the assay specific for ARF1-GTP or ARF6-GTP. The myometrial
tissue lysates, prepared as described above, equivalent to 0.3 mg of
Figure 1. Expression of ARF1, ARF6 and CYTH3 mRNAs in human myometrium. A. RT-PCR analysis of the expression of ARF6, ARF1 and
CYTH1-4 mRNAs in human placenta and myometrium. Lanes 1, MDA-MB-231 cell cDNA (+ve control), 2, water (-ve control), 3, gene specific plasmid
(+ve control), 4, non-pregnant (NP) myometrium cDNA, 5, placental cDNA and 6, -RT NP myometrium cDNA (-ve control). B and C. RT-PCR analysis of
ARF6/ARF1 and CYTH 1-4 mRNA expression, respectively, in human myometrium in different conditions. (i). ARF6, ARF1 and CYTH1-4 cDNA fragments
were amplified from the myometrium of non-pregnant (NP), spontaneous labour (SL), not-in labour (NIL), preterm-spontaneous labour (NP-SL) and
preterm- not in labour (PT-NIL) by PCR using the specific primers shown in Table 1. The intensity of the bands was quantified by densitometric
scanning. The expression levels of ARF6, ARF1 and CYTH3 mRNAs were normalised to the amount of GAPDH in each sample and expressed as
percentage relative to the NP expression (shown as 100%). The histogram represents means 6 SEM of 4 samples for each condition (ii). *represents
P,0.001, One way ANOVA with Tukey’s multiple comparison test.
doi:10.1371/journal.pone.0037954.g001
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PLoS ONE | www.plosone.org 4 May 2012 | Volume 7 | Issue 5 | e37954Figure 2. Immunohistochemical localization of ARF6 and CYTH3 in human uterine tissue sections. A. Sections of human placenta and
liver show clear ARF6 and CYTH3 immunostaining. Negative controls on the right hand side were obtained with pre-immune serum. B. ARF6 and
CYTH3 showing dense intracellular staining in non-pregnant endometrial glands and uniform intracellular staining pattern in both non-pregnant and
pregnant myometrial cells. The images were taken at 406magnification.
doi:10.1371/journal.pone.0037954.g002
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resin coupled to GST-GGA3 PBD fusion protein (3 mg/ml of
resin). The resin was then washed three times with wash buffer
(50 mM Tris-HCl, pH 7.5, 10 mM MgCl2, 150 mM NaCl and
1% Triton X-100). The tissue lysates that were not incubated with
the resin were used as an input controls. The Input and pull-down
resin samples were boiled in the SDS-PAGE sample buffer
(62.5 mM Tris-HCL pH 6.8, 10% Glycerol, 2% SDS, 5% 2-
mercaptoethanol and 0.01% Bromophenol Blue) and analysed by
immunoblotting using an anti-ARF1 or an anti-ARF6 antibody.
Immunoblots were scanned to quantify the intensity of ARF bands
and to calculate the percentage of ARF1 or ARF6 precipitated
from the lysates of myometrial tissues with GST-GGA3 PBD resin.
The GST-GGA3 PBD fusion protein coupled to glutathione beads
as described elsewhere [25].
Densitometry Analysis
Image-J programme was used for densitometric analysis.
Messenger RNA and protein expression levels in different
myometrial samples were normalised using house-keeping gene
GAPDH mRNA and house-keeping protein a-tubulin, respective-
ly. The expression levels were plotted in comparison to the NP
value (100%) where indicated and represented graphically.
Statistical Analysis
The data were analysed using the Graph Pad Prism software.
Multiple group comparison were performed by using the analysis
of variance (ANOVA) and compared with Tukey post-hoc
comparison. P,0.05 was considered to be statistically significant.
Results
Expression of ARF1, ARF6 and CYTH3 mRNAs in Human
Myometrium and Placental Tissue
We investigated first the expression of ARF1, ARF6, CYTH1,
CYTH2, CYTH3 and CYTH4 mRNAs in myometrium by RT-
PCR (Figure 1). Human placental cDNA, where the expression of
ARF6 and CYTH3 mRNAs has been previously reported, MDA-
MB-231 breast cancer cells (which known to express ARF1, ARF6
and CYTH1-4) cDNA and plasmid carrying ARF1, ARF6,
CYTH1, CYTH2, CYTH3 or CYTH4 cDNA were used as
positive controls along with water and –RT cDNA as negative
controls in the RT-PCR analysis [23,26,27,28]. RT-PCR products
of the expected size were obtained only for ARF1, ARF6 and
CYTH3 in myometrium, demonstrating the expression of ARF1,
ARF6 and CYTH3 mRNAs in human myometrium.
ARF1, ARF6 and CYTH3 Gene Expression in Myometrium
does Not Change with Pregnancy or Labour but the
Expression of ARF6 and CYTH3 is Decreased in
Complicated Pregnancies
RNA isolated from myometrial tissue collected from the five
groups of women, NP, NIL, SL, PT-NIL and PT-SL, was
subjected to RT-PCR analysis to determine whether there are any
alterations in ARF1, ARF6, CYTH1-4 genes expression during
pregnancy or labour. Transcripts (mRNAs) for ARF1, ARF6 and
CYTH3 were seen in all the myometrial tissues studied. The
expression of ARF1, ARF6 and CYTH3 mRNAs in the NIL and
SL was comparable with that in NP, suggesting that neither
pregnancy nor the onset of labour have any effect on the
regulation of these genes. However a significant decrease was
observed in the expression of transcripts for ARF6 and CYTH3 in
the PT-NIL group in comparison to the other groups (Figure 1B,
C), indicating a possible association between severe complications
of pregnancy and alterations in ARF6 function.
Immuno-histochemical Analysis of ARF6 and CYTH3 in
Uterine Tissue Sections
The presence of ARF6 and CYTH3 expression was confirmed
by immunohistochemistry. Figure 2 (top panel) shows third
trimester placental villi and human liver stained as positive
controls. In NP uterine sections, there was intense staining of
ARF6 and CYTH3 in the endometrial glands (Figure 2, bottom
panel). Moreover, positive staining was seen for ARF6 and
CYTH3 in both non-pregnant and pregnant myometrial cells,
confirming the validity of the RT-PCR and immunoblotting data.
ARF1, ARF6 and CYTH3 Protein Expression in
Myometrium does Not Change with Pregnancy or Labour
but the Expression of ARF6 and CYTH3 Proteins is
Decreased in Complicated Pregnancies
ARF1, ARF6, CYTH1-4 proteins expression in myometrium
and placenta was analysed by immunoblotting (Figure 3A). The
bands were obtained only for ARF1, ARF6 and CYTH3 in
positive control placenta and myometrium, indicating the expres-
sion of ARF1, ARF6 and CYTH3 but not CYTH1, CYTH2 and
CYTH4 proteins in human myometrium. ARF6 and CYTH3
proteins were expressed in myometrium at lower levels than in
placenta. Although ARF1 and ARF6 are 21 kDa proteins, their
bands appear at a lower position in an immunoblot than expected
due to the N-terminal myristoylation.
Immunoblotting analysis of the five groups of women, NP, NIL,
SL, PT-NIL and PT-SL demonstrated ARF1, ARF6 and CYTH3
but not CYTH1, CYTH1 and CYTH4 protein expression in all
the groups studied (Figure 3B, C). In agreement with the mRNA
results, myometrial ARF1, ARF6 and CYTH3 protein expression
did not change with pregnancy or with the onset of term or
preterm labour. Moreover a significant decrease in both ARF6
and CYTH3 expression was noticed in the PT-NIL group in
comparison to the other groups, confirming that severe compli-
cations of pregnancy may affect myometrial ARF6 expression.
ARF6-GTP Levels in Pregnant and Non-pregnant
Myometrium
The active form of ARF6, ARF6-GTP, interacts with down-
stream effectors to promote reorganisation of actin cytoskeleton. In
order to confirm the functional relevance of the mRNA and
protein expression data, we measured the active GTP-bound
fraction of ARF6 and ARF1 in myometrial extracts. To establish
the validity of the PBD of the human GGA3 effector protein as a
probe to isolate specifically the active GTP-bound form of ARF6,
we pre-treated human myometrial tissue lysates with either
GTPcS or GDP to activate or inactivate ARF6, respectively,
and incubated with GST-GGA3 PBD coupled to glutathione
beads. The protein bound to the beads was analysed by
immunoblotting using ARF6 antibody. As shown in Figure 4.
ARF6 in GTP-bound form, but not in the GDP-bound form, was
specifically pulled-down by the GST-GGA3 PBD beads.
We were able to precipitate ARF6-GTP and ARF1-GTP from
the lysates of placenta and the myometrial lysates in all the groups
of women (Figure 5), confirming the presence of active ARF1 and
ARF6 in non-pregnant and pregnant myometrial tissue and
placenta. ARF1-GTP and ARF6-GTP levels (approximately 10%
of total ARF) remained relatively constant in pregnancy and
labour, but ARF6-GTP levels were significantly decreased in the
PT-NIL group (Figure 5).
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PLoS ONE | www.plosone.org 6 May 2012 | Volume 7 | Issue 5 | e37954Figure 3. Expression of ARF1, ARF6 and CYTH3 proteins in human myometrium. A. Immunoblot analysis of the expression of ARF6, ARF1,
CYTH1-4 and tubulin proteins in human placenta and myometrium. Lanes 1, Placental lysate, and 2, NP myometrium lysate. Immunoblot analysis of
ARF6 and ARF6 (B) and CYTH1-4. (C) protein expression in human myometrium of NP, NIL, SL, NP-SL and PT-NIL. The tissue lysate proteins (50 mg)
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Our study demonstrates for first time the expression of ARF1,
ARF6 and CYTH3 but not the other CYTH family members in
human myometrium. Moreover we were able to demonstrate with
a GST-effector pull down assay that the GTP-bound ARF6 and
ARF1 are present in the tissue, confirming that an active form of
ARF1 and ARF6 are likely to be involved in myometrial function.
The levels of ARF1, ARF6 and CYTH3 remain stable during
pregnancy and labour and the potential role of these proteins in
the maintenance of gestation and the onset of parturition is only
speculative at this stage. RHO proteins have a role in actin
dynamics. Lysophosphatidic acid (LPA)-stimulated stress fibre
formation in Swiss 3T3 cells is mediated by RHO [29] and
involves activation of the PLD signalling pathway [30]. PLD
hydrolyses phosphatidyl choline (PC), the major phospholipids of
membranes, to phosphatidic acid (PA) and choline. PA is involved
in actin reorganization [31]. Recently the role of ARF6 in the PLD
signalling pathway has been implicated as the active ARF6 mutant
(ARF6 Q67L) co-localizes with PLD at the plasma membrane in
Hela cells [32]. CHO cells over-expressing the active ARF6
mutant do not exhibit stress fibre formation in response to LPA in
comparison to non-transfected cells but there was a dramatic effect
on the expression level of RHOA. In this system activation of
ARF6 down regulates RHO signalling [16]. In rat myometrium,
ARF6 was detected exclusively in the membrane fraction and
regulates PLD activity through a mechanism which involves G
protein bc subunits. [17]. The involvement of ARF6 in PLD
activity is of relevance to myometrial responses to endothelin and
tyrosine kinase receptors in rat [17] but such involvement has not
been investigated in human myometrium. From the information
available a direct effect of the ARF6 system in the biochemical
events that trigger term or preterm labour cannot be proposed,
however these are biologically active molecules and further
research is necessary to understand the reason for their presence
in myometrial tissue and alterations in their expression in
complicated pregnancies.
We have demonstrated an increase in active GTP-bound
RHOA in spontaneous preterm labour myometrium [8]. The
active RHOA enhances myometrium contractility by inhibiting
myosin phosphatase through ROCK, and this pathway may be
involved as one of the causative factors in preterm labour. Since
ARF6 activation antagonises RHO-mediated activities, it is
possible that changes in the expression of the ARF6/CYTH3,
and/or ARF6 activation may play a role the development of
premature uterine contractions by increasing RHO activation in
human myometrium. Our data show that ARF6 and CYTH3
expression levels remain relatively constant during normal
pregnancy and labour and we have no evidence of changes in
ARF6-GTP that might relate to alterations in RHO signalling.
Further work is required to investigate the relationship between
ARF6 and RHO in human myometrium.
The regulation of uterine contractility involves input from many
GPCRs present in myometrial cells. In general, stimulatory
receptors promote contractility by increasing intracellular calcium
through a Gq/PLC/PKC pathway whereas inhibitory receptors
promote relaxation by activating the Gs/adenylyl cyclase/cAMP/
PKA pathway. Additional regulatory input is provided by pertussis
toxin sensitive G proteins of the Gi/o family which are substrates
for ADP-ribosylating agents. Gi/o proteins inhibit adenylyl cyclase
and potentiate the stimulatory effect of alpha2A adrenoceptor
(ADRA2A) [33] and OXTR [34]. Uterine GPCRs include
receptors for endogenous stimulatory agonists such as oxytocin
and endothelin as well as inhibitory receptors such as PTGER2,
ADRB2 and LHCGR [8]. ARF6 may have a dual role in
pregnancy: firstly, by promoting uterine quiescence during
ongoing gestation by favouring the desensitization and internal-
ization of stimulatory receptors [35] and secondly by decreasing
the availability of inhibitory receptors [20,36,37] at the time of the
onset of labour, when increased contractility is required. Such
roles would not be necessarily reflected in changes in ARF6
mRNA or protein levels in myometrial tissue with pregnancy or
labour. The role of ARF6 in GPCR desensitisation has been
studied best in relation to the LHCGR in porcine ovarian cells and
it involves liberation of arrestin 2 protein that inhibits the ability of
the receptor to stimulate the Gs/adenylyl cyclase pathway [14].
We have recently analysed the role of ARF6 activation in human
LHCGR internalisation [38], but the involvement of ARF6 in the
functional regulation of stimulatory myometrial receptors other
than endothelin receptor is not known and will be the subject of
our future investigations.
An unexpected finding from this paper was the decrease in
expression of myometrial ARF6/CYTH3 and ARF6-GTP levels
in pregnancies complicated by pre-eclampsia, intrauterine growth
restriction or haemorrhage. ARF6 is a ubiquitous signalling
molecule and it is likely to play an important regulatory role on cell
surface receptors functions in the maternal cardiovascular system,
placenta and other organs involved in fetal growth and homeo-
stasis. Moreover ARF6 can interact with other proteins, for
example ARL4D which is expressed in the uterus, kidney and T
lymphocytes [39]. ARF-like protein (ARL)4D can potentiate
ARF6 effects through CYTH3 translocation to the cell membrane
and coordinated GTPase cascades [40]. It has been shown that in
pre-eclampsia there is a systemic inflammatory response with
increased T cell activation [41] and in this regard ARL4D has
been identified as a target for cytotoxic T lymphocytes [42]. It is
were separated by SDS-PAGE, blotted onto PVDF membranes, and probed with the indicated antibody (i). The lysate of MDA-MB-231 cells was used
as a positive control (+ve) where indicated. The intensity of the bands was quantified by densitometric scanning. The data were normalised to the
amount of tubulin in each sample and shown as means 6 SE of 4 samples in the bottom graph (ii).
doi:10.1371/journal.pone.0037954.g003
Figure 4. GST-GGA3 PBD binding to ARF6-GTP. Myometrium
tissue isolated from non-pregnant woman was lysed and the lysate was
incubated with 0.1 mM GTPcS or 1 mM GDP for 30 min. The
glutathione resin coupled to GST-GGA3 PBD was added to the lysate
and continued the incubation for further 2 h. After washing the beads,
the protein bound to the beads were analysed by immunoblotting
using an anti-ARF6 mouse monoclonal antibody. The lysates that were
not incubated with beads were used as input controls in immunoblot-
ting.
doi:10.1371/journal.pone.0037954.g004
ADP-Ribosylation Factor 6 Signalling in Pregnancy
PLoS ONE | www.plosone.org 8 May 2012 | Volume 7 | Issue 5 | e37954possible that the decrease in myometrial ARF6 expression and
activity, which we have uncovered here, is a reflection of altered
ARF6 signalling in other organs. In most obstetric populations,
including women attending our hospital, there is a clear link
between pre-eclampsia, intrauterine growth restriction and other
risk factors for preterm delivery [43] and alterations in the ARF6
pathway may be a reflection of underlying pathology, however in
this study we did not have enough PT-NIL samples to carry out
multivariable analysis to assess the contribution of each indepen-
dent risk factor. This is an interesting challenge for future research
and further studies in a large cohort of women with complicated
pregnancies are warranted.
In conclusion, we have demonstrated a functional ARF6 system
in human myometrium and an association between ARF6
expression and activity in myometrium and abnormal pregnancy.
Moreover, the present study should pave the way to assess whether
reduction in ARF6 expression and activity is the cause or
consequence in complicated pregnancy. This aspect could be
addressed in future using tissue specific knock out of ARF6 in mice
and/or the specific chemical inhibitor, SecinH3, for the cytohesin
family of ARF GEFs in pregnant mice [38].
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Figure 5. The GST-pulldown analysis of active ARF1 and ARF6 levels in the myometrium. A. Analysis of the ARF1-GTP and ARF6-GTP levels
in human placenta and myometrium. Lanes 1, Placenta and 2, NP myometrium. B. The GST-pulldown analysis of active ARF1 and ARF6 levels in
human myometrium of NP, NIL, SL, NP-SL and PT-NIL. The tissue lysates from NP, NIL, SL, PT-NIL and PT-SL were incubated with GST-GGA3 PBD resin
to precipitate ARF1-GTP or ARF6-GTP as described in the materials and method section. The total ARF1 and ARF6 expression in the cell lysates (upper
panel) and the activated ARF1 and ARF6 that was pulled down with GST-GGA3 PBD (lower panel) were detected by immunoblotting using an anti-
ARF1 rabbit polyclonal and an anti-ARF6 mouse monoclonal antibody respectively (i). The intensity of the bands was quantified by densitometric
scanning. The data were expressed as percentage of total ARF1 or ARF6 that is GTP bound. The histogram represents an average of 4 samples for
each condition (ii).
doi:10.1371/journal.pone.0037954.g005
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